U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H24FN3O4.2H2O
Molecular Weight 425.4512
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BALOFLOXACIN DIHYDRATE

SMILES

O.O.CNC1CCCN(C1)C2=C(OC)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O

InChI

InChIKey=WEGNYJXOCPJAPS-UHFFFAOYSA-N
InChI=1S/C20H24FN3O4.2H2O/c1-22-11-4-3-7-23(9-11)17-15(21)8-13-16(19(17)28-2)24(12-5-6-12)10-14(18(13)25)20(26)27;;/h8,10-12,22H,3-7,9H2,1-2H3,(H,26,27);2*1H2

HIDE SMILES / InChI
Molecular Formula C20H24FN3O4
Molecular Weight 389.4207
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.medicineindia.org/pharmacology-for-generic/2923/balofloxacin http://www.ajptr.com/archive/volume-2/february-2012-issue-1/article-92.html

Balofloxacin (Q-35), is an orally active fluoroquinolone antibiotic. It has been developed for the treatment of urinary tract infection. The bactericidal action of Balofloxacin results from interference with the enqyme DNA gyrase which is needed for the synthesis of bacterial DNA. Balofloxacin is efficacious against Gram-negative bacteria. It also has enhanced activity against Gram positive bacteria, including MRSA and Streptococcus pneumoniae. Side effects of Balofloxacin are: sensitivity to light, abdominal pain, nausea, heartburn, urticarial, irritation when applied locally. Balofloxacin may interact with the following medicines and salts: antacids, non-steroidal anti-inflammatory drug, quinolones, theophylline.

CNS Activity

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
Q-Roxin

Approved Use

Treatment of uncomplicated urinary tract infections

Launch Date

9.7822081E11
Curative
Phase II
1132
Unknown

Approved Use

Unknown
Curative
Approved
8429
Barofloxacin

Approved Use

Barofloxacin is a quinolone antibiotic, prescribed for the treatment of infective ophthalmitis.
Curative
Approved
8429
Balofloxacin

Approved Use

Barofloxacin is a quinolone antibiotic, prescribed for the treatment of skin infections.
PubMed

PubMed

TitleDatePubMed
[Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media].
1996 Aug
History of quinolones and their side effects.
2001
[In vitro antimycobacterial activities of a new quinolone, balofloxacin].
2001 Jan
Balofloxacin Choongwae.
2003 Feb
Electrophysiological safety of novel fluoroquinolone antibiotic agents gemifloxacin and balofloxacin.
2006
Ethyl 1-cyclo-propyl-6,7-difluoro-8-meth-oxy-4-oxo-1,4-dihydro-quinoline-3-carboxyl-ate.
2008 Oct 31
Patents

Patents

US5051509 A
2

Sample Use Guides

In Vivo Use Guide
100 to 400 mg once or twice daily.
Route of Administration: Oral
In Vitro Use Guide
MIC90 of Balofloxacin against clinical isolates of Staphylococcus aureus, methicillin-resistant staphylococcus aureus (MRSA), Staphylococcus epidermidis, Streptococcus pneumoniae, and Streptococcus pyogenes is 6,25 ug/ml.
Substance Class Chemical
Created
by admin
on Sat Dec 16 06:16:54 UTC 2023
Edited
by admin
on Sat Dec 16 06:16:54 UTC 2023
Record UNII
SH1AVB6TVK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BALOFLOXACIN DIHYDRATE
Common Name English
3-QUINOLINECARBOXYLIC ACID, 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-8-METHOXY-7-(3-(METHYLAMINO)-1-PIPERIDINYL)-4-OXO-, DIHYDRATE, (±)-
Common Name English
3-QUINOLINECARBOXYLIC ACID, 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-8-METHOXY-7-(3-(METHYLAMINO)-1-PIPERIDINYL)-4-OXO-, (±)-, DIHYDRATE
Common Name English
(±)-1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-8-METHOXY-7-(3-(METHYLAMINO)PIPERIDINO)-4-OXO-3-QUINOLINECARBOXYLIC ACID, DIHYDRATE
Common Name English
BALOFLOXACIN HYDRATE
JAN  
Common Name English
BALOFLOXACIN HYDRATE [JAN]
Common Name English
3-QUINOLINECARBOXYLIC ACID, 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-8-METHOXY-7-(3-(METHYLAMINO)-1-PIPERIDINYL)-4-OXO-, DIHYDRATE
Common Name English
Code System Code Type Description
PUBCHEM
6918202
Created by admin on Sat Dec 16 06:16:54 UTC 2023 , Edited by admin on Sat Dec 16 06:16:54 UTC 2023
PRIMARY
FDA UNII
SH1AVB6TVK
Created by admin on Sat Dec 16 06:16:54 UTC 2023 , Edited by admin on Sat Dec 16 06:16:54 UTC 2023
PRIMARY
CAS
151060-21-8
Created by admin on Sat Dec 16 06:16:54 UTC 2023 , Edited by admin on Sat Dec 16 06:16:54 UTC 2023
PRIMARY
Related Record Type Details
Structure of BALOFLOXACIN
ANHYDROUS->SOLVATE
Structure of BALOFLOXACIN DIHYDRATE, (R)-
ENANTIOMER -> RACEMATE
Structure of BALOFLOXACIN DIHYDRATE, (S)-
ENANTIOMER -> RACEMATE
Structure of BALOFLOXACIN
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of BALOFLOXACIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966